Methylnaltrexone: Difference between revisions
No edit summary |
No edit summary |
||
| Line 6: | Line 6: | ||
== Development == |
== Development == |
||
In December of 2005, Wyeth and Progenics entered into an exclusive, worldwide agreement for the joint development and commercialization of methylnaltrexone for the treatment of opioid-induced side effects, including constipation and |
In December of 2005, Wyeth and Progenics entered into an exclusive, worldwide agreement for the joint development and commercialization of methylnaltrexone for the treatment of opioid-induced side effects, including constipation and post-operative [[ileus]] (POI), a prolonged dysfunction of the gastrointestinal (GI) tract following surgery. Under the terms of the agreement, the companies are collaborating on worldwide development. Wyeth received worldwide rights to commercialize methylnaltrexone, and Progenics retained an option to co-promote the product in the United States. Wyeth will pay Progenics royalties on worldwide sales and co-promotion fees within the United States. |
||
Methylnaltrexone is being developed in subcutaneous and oral forms to treat |
Methylnaltrexone is being developed in subcutaneous and oral forms to treat opioid induced [[constipation]] (OIC) and an intravenous form for POI. |
||
Progenics and Wyeth are conducting two global phase 3 clinical trials in POI, targeting an NDA submission in this indication in early 2008. An oral formulation for OIC in patients with chronic pain currently is under development with an anticipated NDA submission in late 2009 or early 2010. |
Progenics and Wyeth are conducting two global phase 3 clinical trials in POI, targeting an NDA submission in this indication in early 2008. An oral formulation for OIC in patients with chronic pain currently is under development with an anticipated NDA submission in late 2009 or early 2010. |
||
| Line 14: | Line 14: | ||
{{pharm-stub}} |
{{pharm-stub}} |
||
== |
==References== |
||
* {{cite journal | author=Holzer P | title=Treatment of opioid-induced gut dysfunction | journal=Expert Opin Investig Drugs | year=2007 | pages=181-94 | volume=16 | issue=2 | id=PMID 17243938}} |
* {{cite journal | author=Holzer P | title=Treatment of opioid-induced gut dysfunction | journal=Expert Opin Investig Drugs | year=2007 | pages=181-94 | volume=16 | issue=2 | id=PMID 17243938}} |
||
Revision as of 05:04, 3 November 2007
Methylnaltrexone (MTNX) is one of the newer agents of peripherally-acting mu-receptor antagonists that act to reverse some of the side effects of opioid drugs such as constipation without affecting analgesia or precipitating withdrawals.
Development
In December of 2005, Wyeth and Progenics entered into an exclusive, worldwide agreement for the joint development and commercialization of methylnaltrexone for the treatment of opioid-induced side effects, including constipation and post-operative ileus (POI), a prolonged dysfunction of the gastrointestinal (GI) tract following surgery. Under the terms of the agreement, the companies are collaborating on worldwide development. Wyeth received worldwide rights to commercialize methylnaltrexone, and Progenics retained an option to co-promote the product in the United States. Wyeth will pay Progenics royalties on worldwide sales and co-promotion fees within the United States.
Methylnaltrexone is being developed in subcutaneous and oral forms to treat opioid induced constipation (OIC) and an intravenous form for POI.
Progenics and Wyeth are conducting two global phase 3 clinical trials in POI, targeting an NDA submission in this indication in early 2008. An oral formulation for OIC in patients with chronic pain currently is under development with an anticipated NDA submission in late 2009 or early 2010.
 | This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
References
- Holzer P (2007). "Treatment of opioid-induced gut dysfunction". Expert Opin Investig Drugs. 16 (2): 181–94. PMID 17243938.